Author(s):
Anak Agung Vinidya Githarani, Pande Ayu Naya Kasih Permatananda
Email(s):
nayakasih@gmail.com
DOI:
10.52711/0974-360X.2025.00304 
Address:
Anak Agung Vinidya Githarani, Pande Ayu Naya Kasih Permatananda*,
Pande Ayu Berliana Dekananda Pandit, Luh Gde Evayanthi Faculty of Medicine and Health Science, Warmadewa University, Denpasar, Bali 80239, Indonesia.
*Corresponding Author
Published In:
Volume - 18,
Issue - 5,
Year - 2025
ABSTRACT:
Community acquired pneumonia is one of the infectious diseases of the lungs with high morbidity and mortality rates. Rapid empirical antibiotic administration is needed to overcome this. Length of stay is one of the clinical outcomes in community acquired pneumonia, but until now there is no clear data related to the length of stay associated with the number of empirical antibiotics given to community acquired pneumonia patients. This study aims to see the difference in the length of stay between monotherapy and polytherapy patients. The research method used was descriptive analytic with a cross-sectional approach with the study sample including patients with a diagnosis of community acquired pneumonia and hospitalized who met the inclusion and exclusion criteria. Data collection was taken from medical record data in one of public hospital Bali in 2019. The collected data were analyzed univariately and bivariately. The results obtained from this study were that there was no difference in the median length of stay between monotherapy and polytherapy patients, both of which had a median of 5 days, while significant differences (p=0.01) were seen in the mean length of hospitalization between patients with monotherapy (4.88±2.14) and polytherapy (7.09±3.39) tested by the mann whitney. Further research is needed to clarify the relationship between the addition of empirical antibiotics and length of stay community pneumonia patients.
Cite this article:
Anak Agung Vinidya Githarani, Pande Ayu Naya Kasih Permatananda. Differences in Length of Hospitalization in Pneumonia patients Receiving Monotherapy and Polytherapy Empirical Antibiotic: Study at Tertiary Referral Hospital, Bali. Research Journal of Pharmacy and Technology. 2025;18(5):2121-6. doi: 10.52711/0974-360X.2025.00304
Cite(Electronic):
Anak Agung Vinidya Githarani, Pande Ayu Naya Kasih Permatananda. Differences in Length of Hospitalization in Pneumonia patients Receiving Monotherapy and Polytherapy Empirical Antibiotic: Study at Tertiary Referral Hospital, Bali. Research Journal of Pharmacy and Technology. 2025;18(5):2121-6. doi: 10.52711/0974-360X.2025.00304 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-5-27
REFERENCES:
1. Stotts C, Corrales-Medina VF, Rayner KJ. Pneumonia-Induced Inflammation, Resolution and Cardiovascular Disease: Causes, Consequences and Clinical Opportunities. Circ Res. 2023; 132: 751–74. https://doi.org/10.1161/CIRCRESAHA.122.321636.
2. Zambare KK, Thalkari AB. Overview on Pathophysiology of Pneumonia. Asian J Pharm Res. 2019; 9(3): 177–80. https;//doi.org/10.5958/2231-5691.2019.00028.5.
3. Chellammal R. Bacterial Pneumonia. Asian J Nurs Educ Res. 2014; 4(3): 317–20.
4. Permatananda PANK, Widhidewi NW. Empirical Use of Antibiotics in Pneumonia Patients. Med Respati J Ilm Kesehat. 2021; 16(4): 249–56. https://doi.org/10.35842/mr.v16i4.468.
5. Rana S, Sirwar SB, Vijayaraghavan. Prevalence and Antibiogram of Extended Spectrum β - Lactamase Producing Klebsiella pneumoniae and Proteus mirabilis in UTI. Res J Pharm Technol. 2015; 8(November): 1465–8. httpsz://doi.org/ 10.5958/0974-360X.2015.00262.0.
6. Abbas HA, Kadry AA, Shaker GH, Goda RM. Resistance of Escherichia coli and Klebsiella pneumoniae isolated from different Sources to β -lactam Antibiotics. Res J Pharm Technol. 2017; 10(February): 589–91. https://doi.org/ 10.5958/0974-360X.2017.00116.0.
7. Ervina T, Dharmawan A, Harahap ED, Tan HT, Latifah R. Gambaran Pola Bakteri dan Kepekaan Antibiotik pada Pasien Rawat Inap dengan Pneumonia di Rumah Sakit Paru dr . M . Goenawan Partowidigdo. J Kedokt Meditek. 2021; 27(2): 102–8. https://doi.org/10.36452/jkdoktmeditek.v27i2.1936.
8. Cilloniz C, Rodriguez-Hurtado D, Torres A. Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging. Med Sci. 2018; 6(35): 1–17. https: //doi.org/10.3990/medsci6020035.
9. Syahniar R, Akbar MA, Kharisma DS, Nabila AN. Comparison between monotherapy and combination therapy among inpatients with community-acquired pneumonia. J Ilm Farm. 2021; 17(1): 56–63. https://doi.org/10.20885/jif.vol17.iss1.art6.
10. Kemenkes RI. Hasil Utama Riskesdas 2018. Jakarta: Badan Penelitian Pengembangan Kesehatan Kementerian Kesehatan RI; 2018.
11. Farida Y, Putri VW, Hanafi M, Herdianti NS. Profil Pasien dan Penggunaan Antibiotik pada Kasus Community-Acquired Pneumonia Rawat Inap di Rumah Sakit Akademik Wilayah Sukoharjo. JPSCR J Pharm Sci Clin Res. 2020; 02: 151–64. https://doi.org/10.20961/jpscr.v5i2.39763.
12. Amalia TR, Halimah E, Adrizain R. A Narrative Review Evaluation of Resistance Antibiotics used in Pneumonia. Res J Pharm Technol. 2022; 15(9): 4261–9. https://doi.org/10.52711/0974-360X.2022.00716.
13. Sajinadiyasa IG, Rai IN, Sriyeni L. Perbandingan Antara Pemberian Antibiotika Monoterapi dengan Dualterapi terhadap Outcome pada Pasien Community Acquired Pneumonia (CAP) di Rumah Sakit Sanglah Denpasar. J Intern Med. 2011; 12(1). https://ojs.unud.ac.id/index.php/jim/article/view/3945
14. Stupka JE, Mortensen EM, Anzueto A, Restrepo MI. Community-acquired pneumonia in elderly patients. Aging health. 2009; 5(6): 763–74. https://10.2217/ahe.09.74.Community-acquired.
15. Shivom, Goswani S, Pal N, Singh RP, Singh A. A Meticulous Interpretation on a Sanguinary Disease COVID-19. Res J Pharm Dos Forms Technol. 2020; 12(3): 231–3. https://10.5958/0975-4377.2020.0038.5.
16. Saraswati SI, Bagiada IM, Suardamana K, Kurniari PK. Profil pasien dengan pneumonia komunitas yang dirawat di rsud wangaya denpasar pada bulan oktober 2019 – desember 2019. J Med Udayana. 2022; 11(01): 18–24. https://doi.org/10.24843/MU.2022.V11.i01.P04.
17. Lestarini A, Subrata T, Gunawarman AAGR, Permatananda PANK, Cahyawati PN. Peningkatan Imunitas pada Kelompok Prolanis Puskesmas IV Denpasar Selatan. E-DIMAS J Pengabdi Kpd Masy. 2024; 15(1): 128–35. https://doi.org/10.26877/e-dimas.v15i1.15446
18. Sari EF, Rumende CM, Harimurti K. Factors Related to Diagnosis of Community-Acquired Pneumonia in the Elderly. J Penyakit Dalam Indones. 2016; 3(4): 183–92. https://doi.org/10.7454/jpdi.v3i4.51.
19. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016; 16(10): 626–38. https://doi.org/ 10.1038/nri.2016.90
20. Malik AS, Khan MI. Profiles of community acquired pneumonia cases admitted to a Tertiary Care Hospital. Pak J Med Sci. 2012; 28(1): 75–8. https://pjms.com.pk/index.php/pjms/article/view/2091/379
21. Vaisakh G, Pavithran S, Sigimol K, Sruthimol V. Incidence, risk factors and measures to prevent Ventilator Associated Events (VAE) among mechanical ventilated patients in selected ICU’ s of a tertiary. Int J Nurs Educ Res. 2016; 4(4): 474–80. https://doi.org/ 10.5958/2454-2660.2016.00086.7
22. Sahu S, Sahu P, Singh UR, Singh N. Comprative study of Clinical Parameters of Pneumocystis pneumonia with healthy controls in Vindhya Region. Res J Pharmacogn Phytochem. 2017; 09(02): 59–63. https://doi.org/ 10.5958/0975-4385.2017.00010.3
23. Permatananda PANK. An 8-year-old Marasmic Boy with Miliary Tuberculosis: Case Report. Int Res J Pharm Med Sci. 2022; 5(6): 13–7. https://irjpms.com/wp-content/uploads/2022/09/IRJPMS-V5N6P15Y22.pdf
24. Setiati S. Geriatric Medicine , Sarkopenia , Frailty dan Kualitas Hidup Pasien Usia Lanjut : Tantangan Masa Depan Pendidikan , Penelitian dan Pelayanan Kedokteran di Indonesia. eJKI. 2013; 1(3): 234–42.https://doi.org/10.23886/ejki.1.3008.
25. Sukriya, Manggau MA, Djaharuddin I. Evaluasi Penggunaan Terapi Antibiotik Empiris terhadap Luaran Klinis Pasien Pneumonia Komunitas Rawat Inap. Maj Farm dan Farmakol. 2022; 26(1): 19–25. https://doi.org/ 10.20956/mff.v26i1.18888
26. Hafni I, Darmawan E, Akrom. Evaluasi Terapi Antibiotik pada Pasien Pneumonia Anak Rawat Inap di Rumah Sakit. J Educ Dev. 2023; 11(1): 523–7. https://doi.org/10.37081/ed.v11i1.4435
27. Aprialdi B, Harfiani E, Yusmaini H. Perbandingan Pemberian Obat Seftriakson dan Levofloksasin terhadap Kadar Kreatinin Serum Pasien Pneumonia Rawat Inap di RS Citra Sari Husada Karawang Tahun 2017 - 2018. In: Seminar Nasional Riset Kedokteran (SENSORIK). 2020. p. 41–8. https://conference.upnvj.ac.id/index.php/sensorik/article/view/431
28. Lukitasari N, Radji M, Rianti A. Analisis Perbandingan Antara Monoterapi dengan Dualterapi Antibiotik Extended Empiric pada Pasien Community-Acquired Pneumonia di RSUP Fatmawati Jakarta. J Sains Farm Klin. 2019; 6(2): 147–57. https://doi.org/10.25077/jsfk.6.2.147-157.2019
29. Widyati, Suryajaya IW, Dilaga AA, Hasanah N, Simorangkir R, Hidayaturahmah R. Therapeutic Response of Community Acquired Pneumonia in Geriatrics : A Case Series from Intensive Care Unit. J Farm Klin Indones. 2021; 10(3): 209–16. https://doi.org/10.15416/ijcp.2021.10.3.209
30. Caballero J, Rello J. Combination antibiotic therapy for community- acquired pneumonia. Ann Intensive Care. 2011; 1(48): 1–7. https://doi.org/10.1186/2110-5820-1-48
31. Busi S, Ramanjamma K. Effectiveness of structured teaching programme on level of knowledge and practices regarding prevention of ventilator associated pneumonia among critical care nurses of NRI General Hospital , Guntur , A . P ., India . Int J Adv Nurs Manag. 2016; 4(June): 125–9. https://doi.org/10.5958/2454-2652.2016.00028.7
32. Mahgoub ATE, Elmedani KA, Elkhalifa MY. The influence of Mothers’ Socioeconomic status on Pneumonia in Childhood (Case study in Khartoum State-Sudan ). Res J Humanit Soc Sci. 2013; 4(4): 460–4. https://www.rjhssonline.com/AbstractView.aspx?PID=2013-4-4-6
33. Hiremath D, Desai S. A Study to Assess the Knowledge of mothers of infants regarding Aspiration Pneumonia in selected pediatric Hospital at Bangalore with a view to develop an Information Booklet. Int J Nurs Educ Res. 2020; 08(01): 109–13. https://doi.org/ 10.5958/2454-2660.2020.00023.X